No Data
No Data
10-Q: Q3 2024 Earnings Report
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Keen Vision Acquisition Corp. Merger
Cardiovascular pharmaceutical company Medera plans to go public in the United States through a reverse merger, with a valuation exceeding $0.6 billion.
Medera Inc. has reached an agreement with special purpose acquisition company Keen Vision Acquisition Corp. to go public on Nasdaq through a merger.
10-Q: Q2 2024 Earnings Report
10-Q: Q1 2024 Earnings Report
Keen Vision Acquisition Corporation Announces the Separate Trading of Its Ordinary Shares and Warrants, Commencing September 15, 2023